Paper25751499
Enhanced T-cell immunity to osteosarcoma through antibody blockade of PD-1/PD-L1 interactions.
Lussier DM and 9 others. J Immunother, 2015. Cited by 168 papers, by iCite.
Cite this record
ConductScience Library. Enhanced T-cell immunity to osteosarcoma through antibody blockade of PD-1/PD-L1 interactions. Papers, record 25751499. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/25751499
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Enhanced T-cell immunity to osteosarcoma through antibody blockade of PD-1/PD-L1 interactions.
- PubMed
Topics25
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antibodies, Monoclonal | Major topic |
| B7-H1 Antigen | Major topic |
| Bone Neoplasms | Major topic |
| Immunomodulation | Major topic |
| Osteosarcoma | Major topic |
| Programmed Cell Death 1 Receptor | Major topic |
| T-Lymphocytes | Major topic |
| Adolescent | |
| Adult | |
| Animals | |
| Cell Line, Tumor | |
| Child | |
| Cytokines | |
| Cytotoxicity, Immunologic | |
| Disease Models, Animal | |
| Disease Progression | |
| Gene Expression | |
| Humans | |
| Lymphocytes, Tumor-Infiltrating | |
| Mice | |
| Neoplasm Metastasis | |
| Prognosis | |
| T-Lymphocytes, Cytotoxic | |
| Xenograft Model Antitumor Assays | |
| Young Adult |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| R25 GM071798 | NIGMS NIH HHS | United States | R25GM071798 | PubMed and NIH |
Source NIH RePORTER
References56
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 10561175 | Combined modality treatment for osteosarcoma occurring as a second malignant disease. Cooperative German-Austrian-Swiss Osteosarcoma Study Group. | J Clin Oncol | 1999 | https://conductscience.org/library/papers/10561175 | PubMed |
| 2 | 10850449 | Sequential loss of cytotoxic T lymphocyte responses to simian virus 40 large T antigen epitopes in T antigen transgenic mice developing osteosarcomas. | Cancer Res | 2000 | https://conductscience.org/library/papers/10850449 | PubMed |
| 3 | 12177108 | Effect of timing of pulmonary metastases identification on prognosis of patients with osteosarcoma: the Japanese Musculoskeletal Oncology Group study. | J Clin Oncol | 2002 | https://conductscience.org/library/papers/12177108 | PubMed |
| 4 | 12209992 | Indoleamine 2,3-dioxygenase contributes to tumor cell evasion of T cell-mediated rejection. | Int J Cancer | 2002 | https://conductscience.org/library/papers/12209992 | PubMed |
| 5 | 12663797 | Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment. | J Virol | 2003 | https://conductscience.org/library/papers/12663797 | PubMed |
| 6 | 12743156 | Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. | J Clin Oncol | 2003 | https://conductscience.org/library/papers/12743156 | PubMed |
| 7 | 15240681 | SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. | J Immunol | 2004 | https://conductscience.org/library/papers/15240681 | PubMed |
| 8 | 15705911 | Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. | Cancer Res | 2005 | https://conductscience.org/library/papers/15705911 | PubMed |
| 9 | 16458843 | Management of osteosarcoma pulmonary metastases. | Semin Pediatr Surg | 2006 | https://conductscience.org/library/papers/16458843 | PubMed |
| 10 | 17363529 | PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma. | Clin Cancer Res | 2007 | https://conductscience.org/library/papers/17363529 | PubMed |
| 11 | 17404099 | Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. | Clin Cancer Res | 2007 | https://conductscience.org/library/papers/17404099 | PubMed |
| 12 | 17646988 | Adoptive transfer of autologous, HER2-specific, cytotoxic T lymphocytes for the treatment of HER2-overexpressing breast cancer. | Cancer Immunol Immunother | 2008 | https://conductscience.org/library/papers/17646988 | PubMed |
| 13 | 17656078 | CD8 T cell dysfunction during chronic viral infection. | Curr Opin Immunol | 2007 | https://conductscience.org/library/papers/17656078 | PubMed |
| 14 | 18613845 | Manipulating both the inhibitory and stimulatory immune system towards the success of therapeutic vaccination against chronic viral infections. | Immunol Rev | 2008 | https://conductscience.org/library/papers/18613845 | PubMed |
| 15 | 18676751 | T-cell coregulatory molecule expression in urothelial cell carcinoma: clinicopathologic correlations and association with survival. | Clin Cancer Res | 2008 | https://conductscience.org/library/papers/18676751 | PubMed |
| 16 | 18759925 | Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy. | Immunol Rev | 2008 | https://conductscience.org/library/papers/18759925 | PubMed |
| 17 | 19188168 | Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma. | Clin Cancer Res | 2009 | https://conductscience.org/library/papers/19188168 | PubMed |
| 18 | 19695683 | Increased programmed death-1+ tumor-infiltrating lymphocytes in classical Hodgkin lymphoma substantiate reduced overall survival. | Hum Pathol | 2009 | https://conductscience.org/library/papers/19695683 | PubMed |
| 19 | 20143437 | Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma. | Cancer | 2010 | https://conductscience.org/library/papers/20143437 | PubMed |
| 20 | 20160101 | PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. | Proc Natl Acad Sci U S A | 2010 | https://conductscience.org/library/papers/20160101 | PubMed |
Cited by124
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 168 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42179886 | Immunotherapy and postoperative bone defect repair strategies based on osteosarcoma tumor microenvironment characteristics: balancing antitumor effects and promotion of bone regeneration. | Regen Biomater | 2026 | https://conductscience.org/library/papers/42179886 | PubMed |
| 41681090 | Immune Infiltration Landscape in Osteosarcoma: Clinical Implications for Prognosis and Therapy. | Cancer Rep (Hoboken) | 2026 | https://conductscience.org/library/papers/41681090 | PubMed |
| 41490859 | Hemopurifier device in patients with solid tumours who have stable or progressive disease while on a treatment that includes pembrolizumab or nivolumab: protocol for an Australian safety, feasibility and dose-finding study. | BMJ Open | 2026 | https://conductscience.org/library/papers/41490859 | PubMed |
| 41209019 | Osteosarcoma immunometabolism: emerging mechanisms and clinical implications. | Front Immunol | 2025 | https://conductscience.org/library/papers/41209019 | PubMed |
| 40959529 | Molecular Impact of Magnesium-Mediated Immune Regulation in Diseases. | Scientifica (Cairo) | 2025 | https://conductscience.org/library/papers/40959529 | PubMed |
| 40941025 | The RNA-Binding Protein RBMX Mediates the Immunosuppressive Microenvironment of Osteosarcoma by Regulating CD8+T Cells. | Cancers (Basel) | 2025 | https://conductscience.org/library/papers/40941025 | PubMed |
| 40264674 | Synergistic chemo-immunotherapy for osteosarcoma via a pH-responsive multi-component nanoparticle system. | Front Pharmacol | 2025 | https://conductscience.org/library/papers/40264674 | PubMed |
| 40149640 | Digging Through the Complexities of Immunological Approaches in Emerging Osteosarcoma Therapeutics: A Comprehensive Narrative Review with Updated Clinical Trials. | Biomedicines | 2025 | https://conductscience.org/library/papers/40149640 | PubMed |
| 40119465 | Epigenetic regulators combined with tumour immunotherapy: current status and perspectives. | Clin Epigenetics | 2025 | https://conductscience.org/library/papers/40119465 | PubMed |
| 40099972 | Osteosarcoma Exosome Priming of Primary Human Lung Fibroblasts Induces an Immune Modulatory and Protumorigenic Phenotype. | Cancer Res Commun | 2025 | https://conductscience.org/library/papers/40099972 | PubMed |
| 39995821 | Bibliometric analysis of targeted immunotherapy for osteosarcoma-current knowledge, hotspots and future perspectives. | Front Immunol | 2024 | https://conductscience.org/library/papers/39995821 | PubMed |
| 39916749 | Osteosarcoma: A comprehensive review of model systems and experimental therapies. | Med Res Arch | 2024 | https://conductscience.org/library/papers/39916749 | PubMed |
| 39811323 | T cell receptor signaling pathway subgroups and construction of a novel prognostic model in osteosarcoma. | Heliyon | 2025 | https://conductscience.org/library/papers/39811323 | PubMed |
| 39568569 | Primary osteosarcoma of the breast during lactation: a case report and literature review. | Front Oncol | 2024 | https://conductscience.org/library/papers/39568569 | PubMed |
| 39524888 | Prognostic signature and immunotherapeutic relevance of Focal adhesion signaling pathway-related genes in osteosarcoma. | Heliyon | 2024 | https://conductscience.org/library/papers/39524888 | PubMed |
| 39333065 | Spatial multiplexed immunofluorescence analysis reveals coordinated cellular networks associated with overall survival in metastatic osteosarcoma. | Bone Res | 2024 | https://conductscience.org/library/papers/39333065 | PubMed |
| 39301541 | Case report: pathological complete response after S-1/oxaliplatin regimen combined with trastuzumab and tislelizumab in patients with locally advanced gastric cancer. | Front Oncol | 2024 | https://conductscience.org/library/papers/39301541 | PubMed |
| 39273017 | PAK4 Is Involved in the Stabilization of PD-L1 and the Resistance to Doxorubicin in Osteosarcoma and Predicts the Survival of Diagnosed Patients. | Cells | 2024 | https://conductscience.org/library/papers/39273017 | PubMed |
| 39245737 | Advances on immunotherapy for osteosarcoma. | Mol Cancer | 2024 | https://conductscience.org/library/papers/39245737 | PubMed |
| 38915446 | Advancements in osteosarcoma management: integrating immune microenvironment insights with immunotherapeutic strategies. | Front Cell Dev Biol | 2024 | https://conductscience.org/library/papers/38915446 | PubMed |
Genes14
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/25751499
GET https://conductscience.org/api/papers/v1/25751499/references?page=2